Document is current
Any future updates will be listed below
-
Authors
Lama, Chhiring
Isakov, Danielle
Rosenberg, Shira https://orcid.org/0000-0002-4760-0746
Quijada-Álamo, Miguel
Saurty-Seerunghen, Mirca S.
Moein, Sara
Nozais, Mathis
Abera, Tsega-Ab
Sakaguchi, Olivia
Totwani, Mansi https://orcid.org/0009-0006-4912-3388
Freed, Grace
Zaydon, Leila
Poon, Chi-Lam
Parghi, Neelang
Kubas-Meyer, Andrea
Xie, Amy X. https://orcid.org/0000-0002-1441-7849
Omar, Mohamed
Choi, Daniel
Castillo-Tokumori, Franco https://orcid.org/0000-0002-2245-4068
Abu-Zeinah, Ghaith https://orcid.org/0000-0002-1881-3670
Dillard, Alicia
Ganesan, Saravanan
Omans, Nathaniel D.
Dusaj, Neville
Chamely, Paulina
Mimitou, Eleni https://orcid.org/0000-0001-9737-6394
Smibert, Peter
Kosiorek, Heidi E.
Dueck, Amylou C. https://orcid.org/0000-0002-9912-1085
Weinberg, Rona
Chaligne, Ronan https://orcid.org/0000-0003-4332-3291
Marcellino, Bridget
Marchionni, Luigi https://orcid.org/0000-0002-7336-8071
Patel, Sanjay https://orcid.org/0000-0002-7813-4573
Simonson, Paul
Landau, Dan A.
Wagenblast, Elvin https://orcid.org/0000-0002-0709-2759
Hoffman, Ronald https://orcid.org/0000-0001-6564-6732
Nam, Anna S. https://orcid.org/0000-0003-4192-8916
- License Information
-
More Information
Article History
Received: 9 August 2025
Accepted: 15 August 2026
First Online: 15 September 2026
Ethics
Competing interests: R.H. serves as a consultant to Protagonist, Ionis and Silence Therapeutics and receives research support unrelated to the current study from Dompe, Scholar Rock, Incyte, Novartis, Kartos, Turning Point Therapeutics, Abbvie and Oncomyx. A.S.N. receives research support unrelated to the current study from PharmaEssentia. D.A.L. has served as a consultant for Abbvie and Illumina and is on the Scientific Advisory Board of Mission Bio and C2i Genomics; D.A.L. has received prior research funding from BMS and Illumina unrelated to the current manuscript. The other authors declare no competing interests.
